Michael C Irizarry
Overview
Explore the profile of Michael C Irizarry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weninger S, Irizarry M, Fleisher A, Leon T, Maruff P, Miller D, et al.
Alzheimers Dement (N Y)
. 2025 Jan;
10(4):e70015.
PMID: 39748838
Highlights: The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry and academia, as well as patients, clinicians, and government and regulatory agency scientists to discuss the topic, "Alzheimer's Disease...
2.
Devanarayan V, Charil A, Horie K, Doherty T, Llano D, Andreozzi E, et al.
Alzheimers Dement
. 2024 Nov;
21(2):e14411.
PMID: 39575854
Background: This study examines whether phosphorylated plasma Tau217 ratio (pTau217R) can predict tau accumulation in different brain regions, as measured by positron emission tomography (PET) standardized uptake value ratio (SUVR),...
3.
Leuzy A, Raket L, Villemagne V, Klein G, Tonietto M, Olafson E, et al.
Alzheimers Dement
. 2024 Jul;
20(9):5833-5848.
PMID: 39041435
Introduction: Tau-positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer...
4.
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali L, et al.
Alzheimers Dement
. 2024 Jun;
20(8):5617-5628.
PMID: 38940656
Background: This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels measured by positron emission tomography (PET) Centiloid...
5.
Agarwal K, Backler W, Bayram E, Bloom L, Boeve B, Cha J, et al.
Alzheimers Dement
. 2024 Jan;
20(3):2298-2308.
PMID: 38265159
Despite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public-health burden that LBD imposes is worsened by overlapping...
6.
Iwatsubo T, Irizarry M, Lewcock J, Carrillo M
J Neurosci
. 2023 Nov;
43(47):7894-7898.
PMID: 37968119
Alzheimer's disease (AD) is the major cause of dementia that is now threatening the lives of billions of elderly people on the globe, and recent progress in the elucidation of...
7.
Rafii M, Sperling R, Donohue M, Zhou J, Roberts C, Irizarry M, et al.
Alzheimers Dement
. 2022 Aug;
19(4):1227-1233.
PMID: 35971310
Introduction: The Alzheimer's disease (AD) continuum begins with a long asymptomatic or preclinical stage, during which amyloid beta (Aβ) is accumulating for more than a decade prior to widespread cortical...
8.
Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting
Goldman J, Boeve B, Armstrong M, Galasko D, Galvin J, Irwin D, et al.
Alzheimers Res Ther
. 2021 Jul;
13(1):124.
PMID: 34238345
In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body...
9.
Boxer A, Gold M, Feldman H, Boeve B, Dickinson S, Fillit H, et al.
Alzheimers Dement
. 2019 Nov;
16(1):131-143.
PMID: 31668596
Introduction: Frontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years of age. Increasing numbers of therapeutics targeting FTLD syndromes are being developed. Methods:...
10.
Ten Kate M, Ingala S, Schwarz A, Fox N, Chetelat G, van Berckel B, et al.
Alzheimers Res Ther
. 2018 Nov;
10(1):112.
PMID: 30376881
Background: In Alzheimer's disease (AD), pathological changes may arise up to 20 years before the onset of dementia. This pre-dementia window provides a unique opportunity for secondary prevention. However, exposing...